| 1.78 -0.01 (-0.56%) | 04-14 12:46 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.23 | 1-year : | 2.6 |
| Resists | First : | 1.9 | Second : | 2.23 |
| Pivot price | 1.71  |
|||
| Supports | First : | 1.51 | Second : | 1.26 |
| MAs | MA(5) : | 1.81 |
MA(20) : | 1.63 |
| MA(100) : | 1.79  |
MA(250) : | 2.17 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 80.6 |
D(3) : | 85.1 |
| RSI | RSI(14): 57.1 | |||
| 52-week | High : | 9.18 | Low : | 1.26 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ DARE ] has closed below upper band by 40.9%. Bollinger Bands are 59.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.83 - 1.85 | 1.85 - 1.86 |
| Low: | 1.72 - 1.74 | 1.74 - 1.75 |
| Close: | 1.76 - 1.78 | 1.78 - 1.8 |
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.
Tue, 14 Apr 2026
DARÉ BIOSCIENCE, INC. Files Form 8-K Report with SEC for Unregistered Sales of Equity Securities – April 2026 - Minichart
Mon, 13 Apr 2026
Daré Bioscience Completes Regulation A Preferred Stock Offering - TipRanks
Mon, 13 Apr 2026
Daré Bioscience (NASDAQ: DARE) closes Regulation A sale of 3,470 units - Stock Titan
Thu, 26 Mar 2026
Earnings call transcript: Daré Bioscience Q4 2025 highlights capital efficiency - Investing.com
Thu, 26 Mar 2026
Daré Bioscience, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:DARE) 2026-03-26 - Seeking Alpha
Thu, 26 Mar 2026
Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -1 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 1.456e+007 (%) |
| Held by Institutions | 1.304e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.435e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.21 |
| Profit Margin | 0 % |
| Operating Margin | -162 % |
| Return on Assets (ttm) | 340.7 % |
| Return on Equity (ttm) | -44.8 % |
| Qtrly Rev. Growth | 543.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.636e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -1.49 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 214290 |
| Forward Dividend | 292890 |
| Dividend Yield | 12038800% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|